Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 11/20 | 0.56 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.56 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CTSV | O60911 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6113194 | 0.85 | CYP19A1 (0.53) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL2874685 | 0.82 | PTGDR2 (0.69) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL31418722 | 0.79 | MEN1 (0.70) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL371728 | 0.79 | MEN1 (0.70) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL7825518 | 0.76 | MEN1 (0.67) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL8737543 | 0.76 | MEN1 (0.56) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL11665288 | 0.75 | PTPRC (0.50) | MEN1KMT2AMAPTALDH1A1HTT | |
| SCHEMBL371744 | 0.75 | MEN1 (0.65) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL15814442 | 0.75 | MEN1 (0.65) | MEN1KMT2AMAPTCYP19A1CYP11B1 | |
| SCHEMBL7654335 | 0.75 | MEN1 (0.65) | MEN1KMT2AMAPTCYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703746-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8653270-B2 | Compounds as receptor modulators with therapeutic utility | ALLERGAN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120129813-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | ALLERGAN, INC. | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129813-A1 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY | S1PR1, S1PR3, S1PR2 | MEN1 3560/4885KMT2A 4604/4885MAPT 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.